Kala Pharmaceuticals, Inc. (KALA) News
Filter KALA News Items
KALA News Results
|Loading, please wait...|
KALA News Highlights
- For KALA, its 30 day story count is now at 10.
- Over the past 15 days, the trend for KALA's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- TOP, DRUG and HUGE are the most mentioned tickers in articles about KALA.
Latest KALA News From Around the Web
Below are the latest news stories about KALA PHARMACEUTICALS INC that investors may wish to consider to help them evaluate KALA as an investment opportunity.
For those that want to zig while others zag, these heavily targeted stocks represent the short-squeeze candidates to watch this month.
Shareholders are distrustful How to React (Brief breakdown): Kala Pharmaceuticals, Inc. (NASDAQ:KALA 20.98%), ProQR Therapeutics N.V. (NASDAQ:PRQR 3.64%)
KALA has seen its SMA50 which is now 53.78%. In looking the SMA 200 we see that the stock has seen a 7.40%. PRQR has seen its SMA50 which is … The post Shareholders are distrustful How to React (Brief breakdown): Kala Pharmaceuticals, Inc. (NASDAQ:KALA 20.98%), ProQR Therapeutics N.V. (NASDAQ:PRQR 3.64%) appeared first on Stocks Equity .
In last trading session, Kala Pharmaceuticals Inc. (NASDAQ:KALA) saw 3.03 million shares changing hands with its beta currently measuring -1.58. Company’s recent per share price level of $18.97 trading at $3.29 or 20.98% at ring of the bell on the day assigns it a market valuation of $27.89M. That closing price of KALA’s stock is … Kala Pharmaceuticals Inc. (NASDAQ:KALA) Jumps 20.98%, But Additional Rally May Be Imminent Read More »
Gainers: MicroAlgo (MLGO) +84%.Kala Pharmaceuticals (KALA) +35%.Qualtrics International XM +32%.Qurate Retail (QRTEB) +31%.Scilex Holding SCLX +29%.World Acceptance WRLD +23%.Edible…
Potential short squeeze plays gained steam in 2021 and continued through 2022, with new traders looking for the next huge move. High short interest and a high cost to borrow are among the common traits that could lead to a short squeeze. Here’s a look at the top five short squeeze candidates this week based on the Fintel short squeeze leaderboard and some other stocks to watch moving up the list. See Also: Mark Cuban''s 4 Rules For Making Money Kala Phamaceuticals (NASDAQ: KALA ): Clinical stage biopharmaceutical company Kala tops the leaderboard for the second straight week. Data shows 36.9% of the float short, up from last week’s 36.3% figure. The cost to borrow on shares is 288%, down from last week’s 378.2%. Shares of the Watertown, Massachusetts-based company recently soared after ...
Kala Pharmaceuticals (KALA) was down ~5% pre-market as the company entered into an open market sale agreement with Jefferies for the sale of up to $40M of shares.
The average brokerage recommendation (ABR) for Kala Pharma (KALA) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
RYAM, BUD and KALA made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 17, 2022.
Now may be the time to scoop up high-quality names that continue to trade at very favorable valuations.
In last trading session, Kala Pharmaceuticals Inc. (NASDAQ:KALA) saw 3.68 million shares changing hands with its beta currently measuring -0.55. Company’s recent per share price level of $36.67 trading at -$5.42 or -12.88% at ring of the bell on the day assigns it a market valuation of $36.30M. That closing price of KALA’s stock is … Kala Pharmaceuticals Inc. (NASDAQ:KALA) 90.35% Above Its 52-Week Low, How Long Will It Keep Rising? Read More »